^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/15/2020
Excerpt:
...the NCCN NSCLC Panel recommends erlotinib/ramucirumab as a first-line therapy option for patients with EGFR-positive metastatic NSCLC (category 2A, other recommended intervention) based on clinical data.
